Amarin (AMRN) Competitors

Inventiva has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Inventiva's return on equity of 0.00% beat Amarin's return on equity.

In the previous week, Inventiva had 4 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Inventiva and 0 mentions for Amarin. Inventiva's average media sentiment score of 0.20 beat Amarin's score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amarin presently has a consensus price target of $13.00, suggesting a potential downside of 4.62%. Inventiva has a consensus price target of $15.75, suggesting a potential upside of 316.67%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Amarin.

Amarin has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

Amarin has higher revenue and earnings than Inventiva.

Amphastar Pharmaceuticals has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Amphastar Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Amarin's net margin of -14.56%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Amarin's return on equity.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 0 mentions for Amarin. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat Amarin's score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Amphastar Pharmaceuticals currently has a consensus price target of $22.50, indicating a potential downside of 4.74%. Amarin has a consensus price target of $13.00, indicating a potential downside of 4.62%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Amphastar Pharmaceuticals.

Spyglass Pharma has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Spyglass Pharma's return on equity.

Amarin has higher revenue and earnings than Spyglass Pharma. Amarin is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Spyglass Pharma had 3 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Spyglass Pharma and 0 mentions for Amarin. Spyglass Pharma's average media sentiment score of 0.46 beat Amarin's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the media.

Spyglass Pharma presently has a consensus target price of $44.00, suggesting a potential upside of 51.31%. Amarin has a consensus target price of $13.00, suggesting a potential downside of 4.62%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Spyglass Pharma is more favorable than Amarin.

Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Amarin has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Amarin has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ardelyx has a net margin of -12.35% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Ardelyx's return on equity.

In the previous week, Ardelyx had 15 more articles in the media than Amarin. MarketBeat recorded 15 mentions for Ardelyx and 0 mentions for Amarin. Ardelyx's average media sentiment score of 0.01 beat Amarin's score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Ardelyx presently has a consensus target price of $13.90, suggesting a potential upside of 306.43%. Amarin has a consensus target price of $13.00, suggesting a potential downside of 4.62%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than Amarin.